Postmenopausal hormone therapy—Pretest (optional)

The editors of Sexuality, Reproduction & Menopause would like insight into your current knowledge of treatment with postmenopausal hormone therapy. Your answers to these questions are anonymous and are not linked to your name or CME posttest score.

1) At what age is the prevalence of depression the greatest for a woman?

2030405060

2) Improvement in which of the following menopause-related symptoms is most closely associated with improvement in depression?

Hot flushesVaginal drynessLibidoSleepUrinary frequency

3) The nonhormonal factor best associated with depression during the menopausal transition is:

Prior history of depressionObesityLate menopause (after age 54)Hysterectomy with ovarian conservationPerceived stress

4) Ancillary studies in the Women's Health Initiative (WHI) have shown that in the younger menopausal female (age 50-59)

Coronary heart disease increases and VTE increasesCoronary heart disease decreases and VTE decreasesCoronary heart disease decreases and VTE increasesCoronary heart disease does not change and VTE increasesCoronary heart disease increases and VTE does not change

5) A patient with a balloon endometrial ablation can be treated with a combination estrogen-progesterone transcutaneous patch or

Estrogen therapy aloneProgesterone therapy aloneLong-cycle progesterone therapyProgesterone creamSequential estrogen-progesterone therapy

6) Which of the following is likely to occur when estrogen is opposed with a progestogen every 3 months:

Transitory endometrial hyperplasiaHeavier withdrawal bleedingDecreased compliance with therapyIrregular bleeding patternsIncreased blood pressure

7) Which one of the following symptoms would not be expected upon stopping hormone therapy?

Sleep disturbancesJoint stiffnessVaginal drynessLoss of long-term memoryHeadaches or migraine

8) In studies that have examined women who have stopped hormone therapy, the major reason for restarting hormones is:

Mood changesCognitive declineSevere vasomotor symptomsVaginal drynessWeight gain

9) Which one of the following strategies appears to lessen the discomfort of discontinuing hormone therapy?

Changing to transdermal estrogenStarting a selective serotonin reuptake inhibitorAdding a progestinStarting black cohoshTapering the estrogen dose to every other day

10) In the HOPE trial, lower dosages of unopposed estrogen, ie, 0.3 mg/d and 0.45 mg/d, were associated with:

Increased vaginal bleedingLower incidence of endometrial hyperplasiaIncreased breast tendernessPersistent hot flushesIncreased headaches